Aurobindo Pharma is currently trading at Rs. 1211.90, up by 4.30 points or 0.36% from its previous closing of Rs. 1207.60 on the BSE.
The scrip opened at Rs. 1209.30 and has touched a high and low of Rs. 1225.65 and Rs. 1204.45 respectively. So far 320945 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1292.15 on 07-Jun-2024 and a 52 week low of Rs. 709.00 on 04-Jul-2023.
Last one week high and low of the scrip stood at Rs. 1245.00 and Rs. 1180.80 respectively. The current market cap of the company is Rs. 70810.68 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.30% and 6.87% respectively.
Aurobindo Pharma’s wholly owned step-down subsidiary -- Agile Pharma BV, The Netherlands, has acquired entire share capital of Ace Laboratories, UK, and made it a wholly owned subsidiary of Agile Pharma BV, The Netherlands.
The acquisition is largely for the captive purposes of the company’s business requirements in the European region. Based on capacity utilization, additional external revenue will also add to company’s revenue stream. The cost of acquisition is Rs 17.91 crore on debt free basis.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |